ACADIA Pharmaceuticals (0A4W) Financial Statements
ACADIA Pharmaceuticals Financial Overview
ACADIA Pharmaceuticals's market cap is currently $3.55B. The company's EPS TTM is $2.25; its P/E ratio is 9.15; ACADIA Pharmaceuticals is estimated to report earnings on November 4, 2026, and the estimated EPS forecast is $0.20. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.07B | $ 957.80M | $ 726.44M | $ 517.24M | $ 484.14M |
| Gross Profit | $ 982.51M | $ 875.96M | $ 680.71M | $ 507.07M | $ 465.00M |
| Operating Income | $ 104.81M | $ 230.79M | $ -73.38M | $ -223.60M | $ -170.44M |
| EBITDA | $ 150.66M | $ 100.16M | $ -45.48M | $ -211.42M | $ -164.18M |
| Net Income | $ 391.00M | $ 226.45M | $ -61.29M | $ -215.97M | $ -167.87M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 819.69M | $ 755.99M | $ 438.87M | $ 416.82M | $ 520.71M |
| Total Assets | $ 1.56B | $ 1.19B | $ 748.96M | $ 587.81M | $ 700.12M |
| Total Debt | $ 52.19M | $ 51.99M | $ 57.20M | $ 62.00M | $ 64.43M |
| Net Debt | $ -125.51M | $ -267.59M | $ -131.45M | $ -52.85M | $ -83.00M |
| Total Liabilities | $ 336.81M | $ 454.96M | $ 317.20M | $ 187.40M | $ 159.23M |
| Stockholders' Equity | $ 1.23B | $ 732.79M | $ 431.75M | $ 400.41M | $ 540.89M |
| Cash Flow | |||||
| Free Cash Flow | $ 105.15M | $ 157.20M | $ -23.35M | $ -114.03M | $ -126.78M |
| Operating Cash Flow | $ 109.84M | $ 157.72M | $ 16.70M | $ -114.03M | $ -125.66M |
| Investing Cash Flow | $ -302.56M | $ -30.54M | $ 32.00M | $ 73.24M | $ -71.10M |
| Financing Cash Flow | $ 49.88M | $ 6.84M | $ 25.13M | $ 8.20M | $ 18.16M |
Currency in USD
